Research analysts at William Blair cut their Q1 2025 EPS estimates for Trupanion in a note issued to investors on Thursday, ...

Equities researchers at William Blair increased their Q2 2025 earnings per share estimates for shares of Clearwater Analytics ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

William Blair downgrades Booz Allen, CACI International, Leidos, Parsons and General Dynamics on the heightened risk of ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

William Blair downgraded Booz Allen (BAH) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: See what ...

William Blair International Growth Fund earns an Average Process Pillar rating. The most important driver of the rating is the fund's excellent long-term risk-adjusted performance. This can be ...

William Blair Small-Mid Cap Growth Fund earns a Below Average Process Pillar rating. The process is bolstered by low costs across its parent firm's funds, whose fees rank in their respective ...

William Blair analyst Arjun Bhatia maintained a Buy rating on Radcom (RDCM – Research Report) today. The company’s shares opened today at ...

Repligen Corp (NASDAQ:RGEN) released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago ...